Italia markets closed

PFE Sep 2024 36.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,01000,0000 (0,00%)
In data: 10:09AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0100
Aperto0,0100
Denaro0,0000
Domanda0,0100
Prezzo d'esercizio36,00
Scadenza2024-09-20
Min-Max giorno0,0100 - 0,0100
Contratto - Min-MaxN/D
Volume60
Open Interest4,34k
  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g